GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Akebia Therapeutics

AstraZeneca

FibroGen

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

The current year looks to be ‘shaping up nicely' for GSK PLC (LSE:GSK, NYSE:GSK), according to Barclays Capital in the wake of Wednesday's fourth-quarter and full-year results. It did, however, say it is trimming down forecast sales for HIV products going forward to incorporate 'stocking impacts'.

GSK: Top investment bank has its say after drug giant's better-than-expected results

The US Food and Drug Administration (FDA) has given the green light to Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of adults with chronic kidney disease (CKD) and anaemia who are on dialysis for at least four months. Developed by GSK PLC (LSE:GSK, NYSE:GSK), Jesduvroq is the first innovative medicine for anaemia treatment in over 30 years and the only HIF-PHI approved in the US.

GSK chronic kidney disease drug receives green light

As predicted by some epidemiologists at the onset of the pandemic, COVID-19 would become an endemic flu-like condition not warranting mandated concern. The growth in sales of COVID-19 therapies and diagnostics was not secular, and plummeting Xevudy sales of GSK take the specialty medicines business down a notch.

GSK Shows That The COVID-19 Show Is Passing

GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.

GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook

GSK plc (NYSE:GSK ) Q4 2022 Earnings Conference Call February 1, 2023 6:00 AM ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare & President, Global Health Iain Mackay - CFO & Executive Director Conference Call Participants Kerry Holford - Berenberg Peter Welford - Jefferies Dominic Lunn - Crédit Suisse Timothy Anderson - Wolfe Research James Gordon - JPMorgan Chase & Co. James Quigley - Morgan Stanley Graham Parry - Bank of America Merrill Lynch Emily Field - Barclays Bank Andrew Baum - Citigroup Simon Baker - Redburn Operator Good afternoon, ladies and gentlemen, and welcome to the analyst call of GSK Fourth Quarter 2020 Results. I will now hand you over to Nick Stone, Head of Global Investor Relations, who will introduce today's session.

GSK plc (GSK) Q4 2022 Earnings Call Transcript

Novo Nordisk

Novartis

GSK stock and NVO stock rose Wednesday on fourth-quarter beats, but Novartis stock fell on lighter-than-expected sales despite strong profit. The post Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report appeared first on Investor's Business Daily.

Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report

We heard earlier on Wednesday that GSK PLC (LSE:GSK, NYSE:GSK) could be the first to the market with a drug for RSV, a cold-like condition that can be deadly. Here we take a look at what exactly is and just how big a money spinner it could be for drug companies big and small.

GSK bidding to be first with an RSV vaccine. Here's our 2-minute guide

Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Q4 Earnings and Revenues Top Estimates

GSK PLC (LSE:GSK, NYSE:GSK) has reported better-than-expected fourth-quarter results, largely due to strong sales of its popular shingles vaccine, Shingrix. The pharma giant, which spun out its Haleon consumer business last summer, posted adjusted earnings of 25.8p per share on revenues of around £7.4bn.

GSK 'beats the Street'; enters '23 with strong momentum

GSK PLC on Wednesday posted rising earnings and sales for the fourth quarter, which the company said were boosted by its specialty medicines and vaccines businesses.

GSK posts higher sales and profit of $1.85 billion, lifted by specialty medicines and vaccines businesses

GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix.

GSK Q4 results beat expectations, helped by Shingrix

Entain PLC

Vodafone Group

Kicking off the new month are a trio of intriguing London blue-chips, with the US Fed decision to grab all the headlines later. In London, heavyweight pharma contender GSK PLC (LSE:GSK, NYSE:GSK), which has done well enough since the Haleon consumer products arm was spun out last summer, but investors will feel the shares could do with another shot in the arm.

GSK, Vodafone and Entain all updating, Wednesday's agenda

Pharmaceuticals company GSK has seen a nice run up in price in Q4 2022. But with a rotation in favour of consumer stocks, can this continue? Its upcoming results could be an indicator. With earnings growth expected for 2022, its dividends could rise, adding to its attractiveness.

GSK: A Defensive With A Healthy Dividend Yield

GSK has done well enough since the Haleon consumer products arm was spun out last year, though after a decent run-up to the end of 2022, shares have gone a bit flat since. Fourth quarter and final results next week are expected to show decent underlying profits growth with Shingles vaccine Shingrix expected to continue its recovery from the disruption caused by Covid.

GSK financials should look good but clinic is the focus

GSK plc (NYSE: GSK) is in the running with Moderna Inc. (NASDAQ: MRNA) and Pfizer (NYSE: PFE) to produce respiratory syncytial virus (RSV) vaccines, and analysts outside the company predict it could have a material impact on its topline revenues.

How Could GSK's RSV Vaccine Change its Valuation?

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline

23andMe

Rigel Pharmaceuticals

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

3 Penny Stocks That Could Make You Filthy Rich

GSK is facing a new competitor for its respiratory syncytial virus RSV vaccine after Moderna published data for its alternative, according to analysts at Barclays. “Moderna's efficacy data looks in line with GSK's, and, while there are still a lot of questions to answer (timing of market entry, detailed data, duration of effect), we think GSK's underperformance today reflects consideration of a three-player vs.

GSK faces new RSV vaccine competitor after Moderna data, says Barclays

Moderna

Pfizer

Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks. The post Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market appeared first on Investor's Business Daily.

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market

Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up appeared first on Investor's Business Daily.

Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up

GSK PLC (LSE:GSK, NYSE:GSK) is growing at a "robust" rate and showing increasing confidence in its HIV treatments, according to Jefferies analysts, though they cut their share price target due to long-term challenges and cost worries. Jefferies kept its 'hold' rating and suggested a 2022 price target of 1,575p, a 4% drop on original targets, but this still sits above its current price of 1,415p.

GSK growing optimistic on HIV but long term challenges remain - analyst

GSK plc (NYSE:GSK ) 41st Annual JPMorgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Deborah Waterhouse - CEO of ViiV, HIV business Iain MacKay - Chief Financial Officer Conference Call Participants James Gordon - JPMorgan James Gordon Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst.

GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference (Transcript)

The global pharma sector is expected to see clinical trial readouts that could potentially de-risk approximately US$74bn of peak sales in 2023, according to a research report from Credit Suisse, This is in comparison to US$102bn of readouts in 2022 and US$78bn in 2021, excluding COVID-19-related treatments. The report also found that a record proportion of the 2023 readouts, approximately 40%, will come from line extensions where a drug is already approved for use in a different disease setting.

GSK, AstraZeneca: Will the two UK drugs giants ride the US$74bn pharma wave or will they be left beached?

GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.

News for GlaxoSmithKline Stock (GSK)